Wellcome Leap announces breakthrough in funded project at Caltech – points to new all-in-one vaccine for SARS-like betacoronaviruses – Phase I clinical trials initiated by CEPI
A new nanoparticle-based vaccine has demonstrated broad immune responses in non-human primates against a spectrum of SARS-like betacoronaviruses. The vaccine targets the 'conserved' part of the viral spike, which does not change between variants or animal strains.